
Experimental Gene Therapy for Blindness Considered by the FDA
The U.S. Food and Drug Administration (FDA) is on the brink of approving a type of gene therapy to improve vision loss in people with certain types of blindness. The FDA will decide whether to approve the treatment, known as Luxturna, early in 2018. Luxturna (voretigene neparvovec) is a one-time injectable treatment for a condition